



## Implanet To Participate At The OTCQX International Virtual Investor Conference

**Bordeaux, Boston, May 10, 2017, 8 am** – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announced today that management will participate and present at the OTCQX International Virtual Investor Conference, to be held on Thursday, May 11 at 12:00pm EST (18:00pm CET).



Ludovic Lastennet, CEO of Implanet will present on Thursday, May 11 at 12:00 PM EST (18:00 PM CET) and provide an overview of the Company's business and its recent results. If interested to participate in the OTCQX International Virtual Investor Conference, you can register (free of charge) at: <http://tinyurl.com/0511agendaPR>.

Not Able to Participate, you can still view the Archived webcasts. Archived webcasts will also be available at [www.VirtualInvestorConferences.com](http://www.VirtualInvestorConferences.com) after the event.

### About OTC Markets Group

OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, the group connects a diverse network of broker-dealers that provide liquidity and execution services. OTC Markets also enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

OTC Markets Group in partnership with [VirtualInvestorConferences.com](http://VirtualInvestorConferences.com), a cooperative venture of PR Newswire and Better Investing™ will host the seventh in a series of online investor conferences for companies traded on the OTCQX Best Market.

**Next financial press release:** Q2 2017 revenue, on July 18, 2017

### About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit [www.implanet.com](http://www.implanet.com).

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

#### IMPLANET

Ludovic Lastennet  
CEO  
Tel. : +33 (0)5 57 99 55 55  
[investors@implanet.com](mailto:investors@implanet.com)

#### NewCap

Investor Relations  
Florent Alba  
Tel. : +33 (0)1 44 71 94 94  
[implanet@newcap.eu](mailto:implanet@newcap.eu)

#### NewCap

Media Relations  
Nicolas Merigeau  
Tel. : +33 (0)1 44 71 94 98  
[implanet@newcap.eu](mailto:implanet@newcap.eu)

#### AlphaBronze

US-Investor Relations  
Pascal Nigen  
Tel.: +1 917 385 21 60  
[implanet@alphabronze.net](mailto:implanet@alphabronze.net)